Related Experiment Video

Updated: Feb 18, 2026

Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity
09:32

Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity

Published on: October 17, 2025

565

Incidence and risk of regorafenib-induced hepatotoxicity

Bin Zhao1, Hong Zhao2

  • 1The Second Affiliated Hospital and Yuying Children's Hospital, Wenzhou Medical University, Wenzhou, 325027, China.

Oncotarget
|November 16, 2017
PubMed

Insights

Regorafenib therapy is linked to a higher risk of liver damage, including elevated bilirubin, AST, ALT, and ALP levels. Regular liver function tests are recommended for patients undergoing regorafenib treatment.

Area of Science:

  • Oncology
  • Pharmacology
  • Hepatology

Background:

  • Regorafenib, an oral multi-kinase inhibitor, is used for various cancers.
  • Regorafenib therapy can cause distinct adverse events, notably hepatotoxicity.
  • This study addresses the need for updated data on regorafenib-induced liver toxicities.

Purpose of the Study:

  • To conduct a meta-analysis assessing the incidence and risk of regorafenib-related hepatic toxicities.
  • To provide an up-to-date summary of liver function test abnormalities associated with regorafenib.

Main Methods:

  • Systematic review of PubMed and Embase databases (inception to June 2017).
  • Inclusion of 14 trials with 2,213 subjects treated with regorafenib (160 mg daily).
  • Analysis of safety data for aspartate transaminase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), and bilirubin elevations.

Main Results:

  • Incidences of all-grade hepatotoxicity: bilirubin (23%), AST (32%), ALT (27%), ALP (31%).
  • Incidences of high-grade hepatotoxicity: bilirubin (5%), AST (6%), ALT (5%), ALP (2%).
  • Significant increased risk of all-grade and high-grade elevations in bilirubin, AST, ALT, and ALP in regorafenib-treated subjects.

Conclusions:

  • Regorafenib is associated with an increased risk of hepatic toxicities.
  • Clinicians should monitor liver function at regular intervals during regorafenib therapy.
  • This highlights the importance of proactive management of potential liver damage in cancer patients treated with regorafenib.
Keywords:
adverse eventcancerhepatotoxicityregorafenib

More Related Videos

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer06:21

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer

Published on: May 10, 2024

1.3K
Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

1.2K

Related Concept Videos

Drug Toxicity: Risk factors01:24

Drug Toxicity: Risk factors

Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...
27
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
285
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
212
Hepatic Drug Excretion: Influencing Factors01:16

Hepatic Drug Excretion: Influencing Factors

The biliary system of the liver, crucial for bile secretion and drug excretion, comprises intrahepatic bile ducts that merge to form the common hepatic duct. This duct, carrying hepatic bile, combines with the cystic duct, draining the gallbladder and forming the common bile duct, which empties into the duodenum. Bile, produced by hepatic cells lining the bile canaliculi, is composed primarily of water, bile salts, pigments, electrolytes, and lesser amounts of cholesterol and fatty acids. Bile...
636
Drug Toxicity: Overview01:00

Drug Toxicity: Overview

Drug toxicity quantifies the harm a compound causes to an organism, varying by dose and potentially impacting whole systems or specific organs like the liver. Toxic reactions may arise from venomous insect or spider bites, with effects ranging from mild symptoms to severe outcomes such as brain damage or death. Common forms of acute poisoning include ethanol intoxication and overdose of pain or fever medications, with substances like GHB and heroin being particularly lethal at doses close to...
36
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug01:14

Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug

In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
235